» Articles » PMID: 25953216

Kif20a Inhibition Reduces Migration and Invasion of Pancreatic Cancer Cells

Overview
Journal J Surg Res
Specialty General Surgery
Date 2015 May 9
PMID 25953216
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Translational Genome Research Network in Pancreatic Cancer performed a meta-analysis of publicly available various high-throughput gene analysis panels to identify drugable targets. There, the most differentially expressed gene between normal and cancerous pancreas was Kif20a. The aim of the study was to verify this expression pattern and further characterize Kif20a in pancreatic cancer.

Materials And Methods: Detailed expression analyses were carried out in pancreatic tissues and in a wide panel of pancreatic cells including ductal adenocarcinoma (PDAC) and neuroendocrine-cancer cell lines as well as immortalized human pancreatic ductal epithelial and primary stellate cells using quantitative real-time polymerase chain reaction, immunohistochemistry, immunofluorescence, and immunoblot analyses. Effects on proliferation, apoptosis, and cell cycle were assessed by MTT assays, caspase-cleavage assays, and fluorescence-activated cell sorting analysis after Kif20a silencing. Cell motility was assessed by migration and invasion assays as well as time-lapse microscopy.

Results: Mean Kif20a messenger RNA expression was 18.4-fold upregulated in PDAC tissues compared with that in the normal pancreas. In line, neuroendocrine-cancer cell lines display a 1.6-fold increase and ductal adenocarcinoma cell lines a 11-fold increase of Kif20a messenger RNA (P = 0.009) in comparison with primary stellate cells. A 7.3-fold overexpression was also found in immortalized pancreatic ductal epithelial cells. Kif20a silencing with small interfering RNA molecules resulted in an inhibition of proliferation, motility, and invasion of pancreatic cancer cell lines.

Conclusions: Targeting Kif20a reduces proliferation, migration, and invasion of pancreatic cancer cells. Together with its significant overexpression in PDAC, this makes it a potential target for diagnostic and interventional purposes.

Citing Articles

Identification and validation of KIF20A for predicting prognosis and treatment outcomes in patients with breast cancer.

Yang M, Huang H, Zhang Y, Wang Y, Zhao J, Lee P Sci Rep. 2024; 14(1):31543.

PMID: 39733078 PMC: 11682246. DOI: 10.1038/s41598-024-83362-y.


Loss Promotes Chronic Hepatic Inflammation and Metabolic Dysregulation.

Yang S, Luo T, Liu H, Chen L, Wang J, Zhao Y Genes (Basel). 2024; 15(11).

PMID: 39596644 PMC: 11594155. DOI: 10.3390/genes15111444.


Molecular complex detection in protein interaction networks through reinforcement learning.

Palukuri M, Patil R, Marcotte E BMC Bioinformatics. 2023; 24(1):306.

PMID: 37532987 PMC: 10394916. DOI: 10.1186/s12859-023-05425-7.


Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma.

Di Giorgio C, Bellini R, Lupia A, Massa C, Bordoni M, Marchiano S Front Oncol. 2023; 13:1140730.

PMID: 36998446 PMC: 10043345. DOI: 10.3389/fonc.2023.1140730.


Expression, regulating mechanism and therapeutic target of KIF20A in multiple cancer.

Jin Z, Peng F, Zhang C, Tao S, Xu D, Zhu Z Heliyon. 2023; 9(2):e13195.

PMID: 36798768 PMC: 9925975. DOI: 10.1016/j.heliyon.2023.e13195.